Vivimed Labs Limited VIVIMEDLAB NSEPHARMA
Company Overview
Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India. It operates through two segments, Speciality Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups and liquids, and nasal sprays and ointments. It also exports its products. The company was incorporated in 1988 and is based in Hyderabad, India.
Why Investors Should Care
Generates a return on equity of 83.8%, reflecting efficient use of shareholder capital.
Net profit has compounded at 15.4% per year over the last five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of ₹69.99 Cr (-39.8% YoY); net profit ₹-176.47 Cr.
- Trailing 12 Months Year-on-year growth — revenue -40.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -27.9%, profit CAGR 15.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -27.95% |
| 1 Year: | -40.50% |
Compounded Profit Growth
| 5 Years: | 15.43% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +4.65% |
| 6 Months: | -41.40% |
| 3 Months: | -25.68% |
| 1 Month: | -9.12% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.19 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 83.8%.
- Profit CAGR of 15.4% over 5 years.
- Generates positive free cash flow.
CONS
- Revenue declined at -27.9% CAGR over 5 years.
- Trading 80.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VIVIMEDLAB Vivimed Labs Limited NSEPHARMA | 5.18 | -0.25 | ₹42.95 Cr | 0.00% | -56.38% | 83.81% | -27.95% | 15.43% |
| 2 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,974.50 | 66.71 | ₹1.29 L Cr | 0.22% | 19.79% | 21.50% | 15.33% | 33.34% |
| 3 | ALKEM Alkem Laboratories Limited NIFTY_MIDNSEPHARMA | 5,597.50 | 29.07 | ₹66,926.51 Cr | 0.35% | 18.56% | 17.56% | 8.30% | 32.74% |
| 4 | ABBOTINDIA Abbott India Limited NIFTY_MIDNSEPHARMA | 27,855.00 | 38.12 | ₹59,189.93 Cr | 1.89% | 41.87% | 34.46% | 9.01% | 17.80% |
| 5 | ANTHEM ANTHEM BIOSCIENCES LTD NIFTY_MIDNSEPHARMA | 825.65 | 81.26 | ₹46,377.90 Cr | 0.24% | 26.77% | 19.45% | 26.20% | 15.39% |
| 6 | AJANTPHARM Ajanta Pharma Limited NIFTY_MIDNSEPHARMA | 3,470.40 | 38.28 | ₹43,357.66 Cr | 1.86% | 29.41% | 23.33% | 13.40% | 21.55% |
| 7 | AGARWALEYE DR AGARWALS HEALTH CARE L NSEPHARMA | 532.30 | 127.96 | ₹16,875.30 Cr | 0.00% | 9.74% | 6.58% | 26.96% | 12.28% |
| 8 | APLLTD Alembic Pharmaceuticals Limited NSEPHARMA | 834.45 | 23.67 | ₹16,402.21 Cr | 1.49% | 12.77% | 12.36% | 9.46% | 25.42% |
| 9 | ALIVUS Alivus Life Sciences Limited NSEPHARMA | 1,325.20 | 27.06 | ₹16,265.43 Cr | 0.38% | 21.78% | 16.94% | 7.61% | 6.53% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 25.61 Cr | 21.39 Cr | 20.61 Cr | 15.99 Cr | 12.00 Cr |
| Cost of Revenue | - | 11.45 Cr | 9.80 Cr | 9.12 Cr | 7.90 Cr | 46.93 Cr |
| Gross Profit | - | 14.17 Cr | 11.59 Cr | 11.49 Cr | 8.09 Cr | -34.93 Cr |
| Operating Expenses | - | 22.13 Cr | 16.89 Cr | 17.35 Cr | 23.64 Cr | 116.85 Cr |
| Operating Income | - | -7.96 Cr | -5.29 Cr | -5.86 Cr | -15.55 Cr | -151.79 Cr |
| EBITDA | - | 1.75 Cr | 9.60 L | -74.20 L | -10.92 Cr | -134.53 Cr |
| Interest Expense | - | 1.74 Cr | 57.60 L | 1.66 Cr | 1.00 Cr | 94.70 L |
| Pretax Income | - | -5.49 Cr | -5.49 Cr | -7.30 Cr | -16.55 Cr | -146.99 Cr |
| Tax Provision | - | 11.30 L | 0 | 0 | 0 | 13.80 L |
| Net Income | - | -5.60 Cr | -5.49 Cr | -7.30 Cr | -16.55 Cr | -147.12 Cr |
| Diluted EPS | - | -0.68 | -0.66 | -0.88 | -2.00 | -17.74 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 187.10 Cr | 149.07 Cr | 116.27 Cr | 69.99 Cr |
| Cost of Revenue | - | 279.97 Cr | 77.47 Cr | 59.85 Cr | 73.75 Cr |
| Gross Profit | - | -92.87 Cr | 71.60 Cr | 56.42 Cr | -3.76 Cr |
| Operating Expenses | - | 112.83 Cr | 92.25 Cr | 89.69 Cr | 174.73 Cr |
| Operating Income | - | -205.69 Cr | -20.64 Cr | -33.27 Cr | -178.48 Cr |
| EBITDA | - | -187.24 Cr | -24.67 Cr | -8.68 Cr | -146.11 Cr |
| Interest Expense | - | 35.00 Cr | 1.21 Cr | 2.95 Cr | 4.17 Cr |
| Pretax Income | - | -330.65 Cr | -45.82 Cr | -31.85 Cr | -176.34 Cr |
| Tax Provision | - | -2.12 Cr | -37.70 L | 11.30 L | 13.80 L |
| Net Income | - | -328.54 Cr | -45.45 Cr | -31.96 Cr | -176.47 Cr |
| Diluted EPS | -8.16 | -39.62 | -5.48 | -3.85 | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 995.05 Cr | 950.91 Cr | 920.83 Cr | 753.48 Cr |
| Current Assets | - | 338.99 Cr | 342.58 Cr | 327.55 Cr | 168.00 Cr |
| Cash & Equivalents | - | 3.76 Cr | 1.63 Cr | 70.80 L | 1.36 Cr |
| Inventory | - | 79.76 Cr | 64.06 Cr | 58.75 Cr | 12.71 Cr |
| Receivables | - | 74.16 Cr | 82.82 Cr | 74.11 Cr | 45.33 Cr |
| Total Liabilities | - | 955.63 Cr | 956.37 Cr | 956.00 Cr | 964.03 Cr |
| Current Liabilities | - | 424.09 Cr | 410.33 Cr | 408.20 Cr | 448.11 Cr |
| Long Term Debt | - | 62.32 Cr | 63.56 Cr | 63.62 Cr | 71.51 Cr |
| Total Debt | - | 381.03 Cr | 378.79 Cr | 376.33 Cr | 397.31 Cr |
| Total Equity | - | 39.42 Cr | -5.46 Cr | -35.17 Cr | -210.55 Cr |
| Shares Outstanding | - | 8.29 Cr | 8.29 Cr | 8.29 Cr | 8.29 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 35.32 Cr | -23.99 Cr | -1.15 Cr | 7.70 Cr |
| Investing Cash Flow | - | -4.97 Cr | 28.29 Cr | -4.53 Cr | -94.70 L |
| Financing Cash Flow | - | -33.78 Cr | -6.03 Cr | 4.36 Cr | -6.11 Cr |
| Capital Expenditure | - | -4.97 Cr | -2.04 Cr | -4.53 Cr | -94.70 L |
| Free Cash Flow | - | 30.35 Cr | -26.03 Cr | -5.68 Cr | 6.76 Cr |
| Net Change in Cash | - | -3.43 Cr | -1.74 Cr | -1.32 Cr | 64.90 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | -49.6% | 48.0% | 48.5% | -5.4% |
| Operating Margin % | - | -109.9% | -13.8% | -28.6% | -255.0% |
| Net Margin % | - | -175.6% | -30.5% | -27.5% | -252.1% |
| ROE % | - | -833.4% | 832.2% | 90.9% | 83.8% |
| ROCE % | - | -36.0% | -3.8% | -6.5% | -58.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VIVIMEDLAB
Vivimed Labs Limited Revenue Breakdown – NSE:VIVIMEDLAB - TradingView
<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTE9TOWhVZDNDVHdjRUxVWnNiekJseG1NYngtSEF0eUZSRWxoNW9fWjZkR2cwa1ptWUpZYWF5VDhNOUhIX1RaWi1iQ3ZKeEw3eDNSdmhhS1ZUb0VkQ2VhS2NJMURudnJQYXhnVmZ5cWFWSXZWMUFiMV9nRFNVYw?oc=5" target="_blank">V…
Vivimed Labs Limited's (NSE:VIVIMEDLAB) 31% Dip In Price Shows Sentiment Is Matching Revenues - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPNHpQV1BXTGlRZEIxeXQzaURfNURaQm1DT09FLXotMmJGMTEzUFhFaHJ6M2gyNjVIS0FDYXpKVE1VTHRnQ3VGZnBzcXRjeG44NFU5LXZSdXdCVHNjSFM0eTBEdF9MOTFEUHJPNGlncUFJSi14eHE0blRCMFV3SnJBMG9tQlRLcUxNZ1VCbz…
VIVIMEDLAB Stock Price and Chart — NSE:VIVIMEDLAB - TradingView
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE0xNjQ2ZFItcTh4aU1NR0o4Zl9qYTZTa2hlUjJGNjhJcmpwelJxZ1ZlQ3RUVXYyc3Rkc2cwdVVGVUFPTWJudnlGeG1WMGM1RVpTWHd1dFd0R2hJRXNzblNQNg?oc=5" target="_blank">VIVIMEDLAB Stock Price and Chart — NS…
Vivimed Labs Ltd. Share Price Today | Vivimed Labs Live NSE/BSE - Value Research
<a href="https://news.google.com/rss/articles/CBMidEFVX3lxTE9HcFJGa0pydUNFMHhHaVZzLTIxTkxaUE51OUxDRmp0ekE3TmlfT3JERGI2M1VJbXlUV0ZEU3p2eVltQVFXQ3Q0NEloLUd1bFRTM0hpX1dzWnRSMFgzWVlqS29sdVhoZlI4My1qTHZwR09RRUJv?oc=5" target="_blank">Vivimed Lab…
Vivimed Labs Secures High Court Interim Stay on CBI Case and Bank Fraud Declaration - scanx.trade
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxNaG51Z0NyQWpEbmtBOHhXZ3BlMFcxczk2TUVxODFKUHQwQmlKcHBkY0RpczVka2p0anphMUJtR3hLOF9fV2VpOEZWQlA3RDAyNmhremJQb2ZJSWQ1eG5tb21oWkJkbVlJTk82YmZZZnNjdlRfREZZckVBbEVHZ3FfSmluNDVsOThWMmtWLT…
VIVIMEDLAB — Frequently Asked Questions
What is the current share price of Vivimed Labs Limited (VIVIMEDLAB)?
As of 2026-08-07 06:31 IST, Vivimed Labs Limited (VIVIMEDLAB) trades at ₹5.18 on NSE. Its 52-week range is ₹4.95 to ₹26.60.
What is the market capitalisation of VIVIMEDLAB?
Vivimed Labs Limited (VIVIMEDLAB) has a market capitalisation of ₹42.95 Cr on NSE.
What is the P/E ratio of VIVIMEDLAB?
VIVIMEDLAB trades at a trailing price-to-earnings (P/E) ratio of -0.25. The industry average P/E is 35.94. Its price-to-book (P/B) ratio is -0.87.
What is the return on equity (ROE) of VIVIMEDLAB?
VIVIMEDLAB has a return on equity (ROE) of 83.81%. Its return on capital employed (ROCE) is -56.38%.
Is VIVIMEDLAB a good stock to buy?
This page provides a data-driven analysis of Vivimed Labs Limited (VIVIMEDLAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.